Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.34 |
| ▸ | FLT1 | P17948 | 1/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | RAF1 | P04049 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2243645 | 0.94 | ALDH1A1 (0.39) | BRD4ALDH1A1KDM4EALOX5MAPT | |
| SCHEMBL24306858 | 0.86 | PKM (0.40) | BRD4ALDH1A1KDM4EALOX5MAPT | |
| SCHEMBL25942010 | 0.86 | GAA (0.39) | BRD4ALDH1A1KDM4EMAPTLMNA | |
| SCHEMBL24306365 | 0.85 | GAA (0.34) | ALDH1A1KDM4EALOX5SMN1; SMN2RAF1 | |
| SCHEMBL2240754 | 0.84 | BRD4 (0.52) | BRD4ALDH1A1KDM4EALOX5MAPT | |
| SCHEMBL2239931 | 0.83 | BRD4 (0.39) | BRD4ALDH1A1KDM4EALOX5MAPT | |
| SCHEMBL2247042 | 0.83 | CFTR (0.37) | BRD4ALDH1A1KDM4EALOX5MAPT | |
| SCHEMBL28965622 | 0.82 | SIRT6 (0.39) | BRD4ALDH1A1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL8004920 | 0.80 | ALOX5 (0.54) | ALDH1A1KDM4EALOX5MAPTSMN1; SMN2 | |
| SCHEMBL30035530 | 0.80 | ALOX5 (0.54) | ALDH1A1KDM4EALOX5MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365558-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230365558-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2023-11-16 | — | — | US | disclosed |
| EP-4219461-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF | Medshine Discovery Inc. (CN) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022063094-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF | 南京明德新药研发有限公司 | 2022-03-31 | — | — | WO | disclosed |
| US-8389511-B2 | Bicyclic heterocyclic derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-03-05 | — | — | US | disclosed |
| US-8389511-B2 | Bicyclic heterocyclic derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-03-05 | — | — | US | disclosed |
| US-20110190278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO. | 2011-08-04 | — | — | US | disclosed |
| US-20110190278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO. | 2011-08-04 | — | — | US | disclosed |
| EP-2243779-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2010-10-27 | — | — | EP | disclosed |
| EP-2243779-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2010-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | REN, AGTR1, AGTR2 | BRD4 67/4885ALDH1A1 288/4885KDM4E 2766/4885 |
| US-20230365558-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF | CYP3A7, UGT2B7, SFPQ | BRD4 225/4885ALDH1A1 1495/4885KDM4E 2152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.